Items Tagged ‘jakafi’

December 27, 2017

Long Term Follow Up Shows Durability of Jakafi® Response in Patients with Polycythemia Vera

By

CancerConnect News: Jakafi® (ruxolitinib) was initially reported to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than the best available therapy at the 56th American Hematology Society Annual Meeting in 2014.1,2 Now with a full 4 years of follow-up from this trial the benefit of Jakafi® continues to be confirmed. Results recently presented […]

View full entry

Tags: clinical trial, Incyte, jakafi, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, RESPONSE, ruxolitinib


December 6, 2017

Fedratinib May Represent New Option for Jakafi-Resistant Myelofibrosis

By

Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal Lancet.1 About Myelofibrosis Myelofibrosis is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in […]

View full entry

Tags: essential thrombocytosis, fedratinib, jakafi, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, News, polycythemia vera, ruxolitinib


November 22, 2017

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia

By

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea (HU). “We are pleased to treat the first patient in our pivotal trial evaluating ruxolitinib as a […]

View full entry

Tags: essential thrombocythemia, ET, Incyte Corporation, jakafi, Myeloproliferative Neoplasms MPN, News, RESET Clinical Trial, ruxolitinib